Bank of Montreal
ALNY icon

Bank of Montreal’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank of Montreal’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,400
Closed -$6.11M – 4747
2020
Q2 		$6.11M Buy
+38,400
New +$5.18M 0.01% 1076

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of Montreal's ALNY Position: Q2 2026 in Review

Bank of Montreal increased its Alnylam Pharmaceuticals (ALNY) stake by 3% in Q2 2026, buying an estimated $293K and bringing the position to 32,834 shares worth $9.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Bank of Montreal first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $15.9M in Q1 2024. 504 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bank of Montreal held 32,834 shares of Alnylam Pharmaceuticals worth $9.88M as of Q2 2026.
  • Bank of Montreal bought 970 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $293K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1163 holding.
  • Bank of Montreal first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of Montreal's Alnylam Pharmaceuticals position peaked at $15.9M in Q1 2024.
  • 504 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.